Therapie最新文献

{"title":"Impact of new drug releases on heart failure management and hospitalizations in France: A repeated cross-sectional study between 2014 and 2023","authors":"Paul Gautier ,&nbsp;Cécile Vindis ,&nbsp;Meyer Elbaz ,&nbsp;François Montastruc","doi":"10.1016/j.therap.2024.07.006","DOIUrl":"10.1016/j.therap.2024.07.006","url":null,"abstract":"<div><div>Real-life data on the impact of sacubitril-valsartan and sodium-glucose cotransporter type 2 (SGLT-2) inhibitors on heart failure (HF) in France is lacking. Using French health insurance databases, we examined the ten-year evolution in HF medication use, focusing on SGLT-2 inhibitors and sacubitril/valsartan, and incidence of HF hospitalizations during the same period. We conducted a repeated cross-sectional study using medical-administrative data from French health insurance databases between 2014 and 2023. These included “OpenMedic” for outpatient medication reimbursements and “ScanSanté” for annual hospitalization data. Medications were classified using ATC codes, and hospitalizations were identified using ICD-10 codes. Statistical analyses encompassed annual rates of users and boxes dispensed for HF medications, along with HF, ischemic heart disease and ischemic stroke hospitalization rates. Prevalence of SGLT-2 inhibitors and sacubitril-valsartan use was also studied regionally, with direct standardization by age and sex, with the French population as the standard population. Between 2014 and 2023, HF drug use increased significantly, with beta-blockers and ACE inhibitors/ARBs leading in prevalence of use. ARNi and SGLT-2 inhibitors, introduced later, showed remarkable rises: +506% and +3766% in users since their market introduction, respectively. Meanwhile, HF hospitalizations slightly increased by +3.6% between 2016 and 2019, followed by a notable decline of −12.5% during 2019–2023, coinciding with the introduction of SGLT-2 inhibitors. In contrast, hospitalizations for ischemic heart disease rose by 11.6% over the period 2016–2019 and by +5.2% over the period 2019–2023, and hospitalizations for ischemic stroke rose by 8.2% over the period 2016–2019 and declined by −0.6% over the period 2019–2023. We observed regional disparities in SGLT-2 inhibitors use, with prevalence ranging from 0.9% in Bretagne to 1.5% in Hauts-de-France. The data suggests a temporal correlation between the increase in SGLT-2 inhibitors use and the decline in HF hospitalizations since 2019. More studies are needed to measure real life effectiveness of SGLT-2 inhibitors in heart failure.</div></div>","PeriodicalId":23147,"journal":{"name":"Therapie","volume":"80 3","pages":"Pages 253-258"},"PeriodicalIF":2.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142037105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Case report: Spontaneous splenic rupture concomitant with serum sickness induced by infliximab.","authors":"Thomas Darque, Arthur Dubernet, Chloé Martineau, Julia Goossens, Marie-Laure Jullie, Nathalie Sultan","doi":"10.1016/j.therap.2025.04.004","DOIUrl":"https://doi.org/10.1016/j.therap.2025.04.004","url":null,"abstract":"","PeriodicalId":23147,"journal":{"name":"Therapie","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144133237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Blood glutamate levels in major depression with antidepressants and benzodiazepines: A 6-month prospective cohort study.","authors":"Kahlil El Asmar, Tala El Ghoul, Romain Colle, Rida Assaf, Séverine Martin, Séverine Trabado, Bruno Feve, Céline Verstuyft, Laurent Becquemont, Emmanuelle Corruble","doi":"10.1016/j.therap.2025.04.003","DOIUrl":"https://doi.org/10.1016/j.therap.2025.04.003","url":null,"abstract":"<p><strong>Aim of the study: </strong>Our study aims at analyzing blood glutamate levels at three time points in patients on antidepressants and benzodiazepines across different subgroups.</p><p><strong>Methods: </strong>In the 6-month METADAP cohort study, blood glutamate levels were measured in 60 patients with major depression at baseline, 3 months (M3), and 6 months (M6) after starting antidepressant treatment. All patients received a co-prescription with benzodiazepines. Mixed-effect linear regression models were used to analyze the correlation of glutamate levels over time among responders, non-responders, remitters, and non-remitters, adjusting for multiple confounders.</p><p><strong>Results: </strong>Glutamate blood levels showed a significant decrease. Glutamate levels decreased from M0 to M3 across all subgroups. Responders and remitters showed a further decline from M3 to M6 while they increased non-significantly from M3 to M6 among non-responders and non-remitters. Responders showed a decrease of 3.38μmol/L [95% CI (-4.94; -1.82), P<0.001], while remitters showed a decrease of 1.34μmol/L [95% CI (-2.41; -0.27), P=0.014].</p><p><strong>Conclusion: </strong>Glutamate blood levels decreased from M0 to M3 across all groups but varied from M3 to M6: responders and remitters continued to decline, while non-responders and non-remitters showed a non-significant increase. These results should be replicated and further explained.</p>","PeriodicalId":23147,"journal":{"name":"Therapie","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144000863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Subcutaneous rituximab in indolent primary cutaneous B cell lymphoma: A case series of 5 patients with the evaluation of the medico economic impact.","authors":"Carla Fassanaro, Laurent Mortier, Olivier Carpentier, Inès Arib, Benoit Dervaux, Sarah Faiz","doi":"10.1016/j.therap.2025.04.001","DOIUrl":"https://doi.org/10.1016/j.therap.2025.04.001","url":null,"abstract":"","PeriodicalId":23147,"journal":{"name":"Therapie","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144045041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rapid desensitization to insulin in a patient with diabetic ketoacidosis and insulin allergy.","authors":"Emna Chtourou, Fatma Charfi, Imen Chabchoub, Hanen Ghozzi, Ahmed Hakim, Kammoun Thouraya, Khaled Zeghal, Lobna Ben Mahmoud","doi":"10.1016/j.therap.2025.03.004","DOIUrl":"https://doi.org/10.1016/j.therap.2025.03.004","url":null,"abstract":"","PeriodicalId":23147,"journal":{"name":"Therapie","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143983041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preventing shingles starts with vaccinating against chickenpox.","authors":"Michaël Rochoy","doi":"10.1016/j.therap.2025.03.003","DOIUrl":"https://doi.org/10.1016/j.therap.2025.03.003","url":null,"abstract":"","PeriodicalId":23147,"journal":{"name":"Therapie","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144055146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reintroduction of cotrimoxazole in a Stevens-Johnson case with other antibacterial sulfonamide (sulfadiazine) among suspects.","authors":"Ilaria Matei, Valérie Beaulieu, Camille Ollivier, Bénédicte Lebrun-Vignes, Kamar Bel Hareth, Saskia Ingen-Housz-Oro, Haudrey Assier","doi":"10.1016/j.therap.2025.03.002","DOIUrl":"https://doi.org/10.1016/j.therap.2025.03.002","url":null,"abstract":"","PeriodicalId":23147,"journal":{"name":"Therapie","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143796262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Usefulness of thiopurines therapeutic drug monitoring in patients with inflammatory bowel disease.","authors":"Zohra Chadli, Ibtissem Hannachi, Nadia Ben Fredj, Hichem Loghmari, Haifa Ben Romdhane, Ahlem Slama, Amel Chaabane, Leila Safer, Karim Aouam","doi":"10.1016/j.therap.2025.03.001","DOIUrl":"https://doi.org/10.1016/j.therap.2025.03.001","url":null,"abstract":"<p><strong>Introduction: </strong>Thiopurine drugs, the most commonly prescribed immunosuppressive agents used in the treatment of inflammatory bowel disease (IBD), are characterized by a narrow therapeutic window, which makes therapeutic drug monitoring (TDM) of thiopurine metabolites recommended. 6-thioguanine nucleotides (6-TGN) are considered the most active metabolites of the thiopurines and they are responsible for therapeutic efficacy and correlate with myelotoxicity. This present study aims to assess the usefulness of 6-TGN monitoring in Tunisian patients with IBD.</p><p><strong>Patients and methods: </strong>We performed a retrospective study including patients with IBD treated by azathioprine and underwent a TDM of 6-TGN between May 2018 and December 2023. Samples of venous blood were collected at 2hours after medication intake. Concentrations values were determined, at the steady-state, using a technique of High-performance liquid chromatography (HPLC). Correlations between the 6-TGN concentrations and hematological parameters were assessed by Pearson's correlation coefficient.</p><p><strong>Results: </strong>A total of 140 patients were included (65 men/75 women). The average concentration was 386.2±258.9pmol/8×10⁸ RBCs. After an initial dose, only 49% of the patients had 6-TGN concentrations in the target range. The multiple TDM after AZA dose adjustment has shown improvement of the probability of obtaining 6-TGN concentration in the target range (69%). In our study, we demonstrated that 6-TGN concentrations were inversely correlated with hemoglobin levels, white cell, and neutrophil counts.</p><p><strong>Conclusion: </strong>We have shown the usefulness of AZA TDM by determining the 6-TGN metabolite concentrations in Tunisian patients. However, this approach remains insufficient to optimize the treatment by azathioprine. Other approaches, such as genotyping patients for TPMT and NUD15 and adjusting AZA doses based on population pharmacokinetic models, appear to be essential for optimizing AZA therapy.</p>","PeriodicalId":23147,"journal":{"name":"Therapie","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144035875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perceptions of contribution of the placebo effects to drug efficacy in community pharmacy practice: A cross-sectional survey.","authors":"Joey Fournier, Leo Druart, Marie Allier, Matthieu Roustit","doi":"10.1016/j.therap.2025.02.015","DOIUrl":"https://doi.org/10.1016/j.therap.2025.02.015","url":null,"abstract":"<p><strong>Introduction: </strong>The placebo effect, a well-documented phenomenon in clinical practice, remains complex and multifaceted. While the perception of placebo effects has been assessed among various healthcare professionals, pharmacists - recognized experts in treatment effects and effectiveness - have not been specifically studied. This cross-sectional study aimed to evaluate the knowledge and perceptions of healthcare professionals working in community pharmacies in France, Switzerland, and Belgium regarding placebo effects.</p><p><strong>Material and methods: </strong>A self-administered questionnaire was distributed to pharmacists, pharmacy technicians, and community pharmacy students between September and December 2023. The questionnaire used numeric scales (0-10) to evaluate knowledge of placebo effects, underlying mechanisms, influencing factors, and demographic details.</p><p><strong>Results: </strong>A total of 377 responses were collected, primarily from female pharmacists practicing in France. Respondents demonstrated a strong theoretical understanding of placebo effects (n=302; 80%). Among 12 proposed contextual factors influencing placebo effects, the three most highly rated were patient-related: patient expectations and preferences, past experiences, and beliefs or representations about their condition. Perceptions of placebo effects varied significantly according to medication type, with median scores of 1 [0-3] for treatments with demonstrated efficacy, 3 [1-5] for conventional medicines without demonstrated efficacy, and 6 [4-9] for complementary and alternative medicines (CAM). This suggests that placebo-related efficacy is perceived as more associated with the type of medication (e.g., CAM vs. conventional medicines) rather than the presence or absence of demonstrated efficacy.</p><p><strong>Conclusion: </strong>Pharmacists showed a solid theoretical grasp of placebo effects but seem to associate placebo-related efficacy more strongly with medication type than evidence of efficacy. These findings highlight the need to raise awareness among pharmacy-based healthcare professionals about treatment efficacy to improve clinical practice and patient care.</p>","PeriodicalId":23147,"journal":{"name":"Therapie","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143773398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unexpected haloperidol-induced yawning while neuroleptic switch, paradoxical reaction or dopaminergic supersensitivity? A case report.","authors":"Jacques Hamard, François Montastruc, Dalil Boulefaa, Julie Haybrard, Julien Li","doi":"10.1016/j.therap.2025.02.014","DOIUrl":"https://doi.org/10.1016/j.therap.2025.02.014","url":null,"abstract":"","PeriodicalId":23147,"journal":{"name":"Therapie","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143796310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}